Drugs / 18F-PF-06445974
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07027839 | Dec 2025 → Feb 2028 expected | alcohol-related disorders | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
| Phase 1 | NCT06795581 | Mar 2025 → Dec 2028 expected | alcohol-related disorders | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
| Phase 1 | NCT05703685 | Jun 2023 → Oct 2028 expected | depressive disorder | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-PF-06445974 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06795581 ↗ |
| Known as | [18F]PF974 | “Using the PET radioligand \[18F\]PF-06445974 (Hereafter referred to as \[18F\]PF974) to measure PDE4B binding in the brain” NCT07027839 ↗ |
| Known as | PF-06445974 F-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316160 ↗ |
| Modality | Diagnostic / imaging agent | “experimental substance called a radioactive tracer” NCT05703685 ↗ |
| Route | Intravenous | “Injected IV followed by PET scanning” NCT05703685 ↗ |
| Target | PDE4B | “to Image PDE4B” NCT05703685 ↗ |